Aktienanalyse zu Precigen Inc (PGEN)PGENPrecigen Inc

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Precigen Inc (PGEN) is a good buy right now due to its recent strong financial performance, including a 145% revenue growth in Q2 2026, with total revenue reaching $55 million. Additionally, the stock has a favorable analyst price target of $12, which implies a potential upside of 53.5% from the current price of $7.81. However, a key risk is the high debt to equity ratio of 215.44%, indicating potential financial instability.